Literature DB >> 24726456

Suppressor of cytokine signaling 1 modulates invasion and metastatic potential of colorectal cancer cells.

Muriel David1, Cécile Naudin2, Martine Letourneur1, Mélanie Polrot3, Jack-Michel Renoir1, Vladimir Lazar4, Philippe Dessen4, Serge Roche2, Jacques Bertoglio1, Josiane Pierre5.   

Abstract

Suppressor of cytokine signaling (SOCS) 1 is an inducible negative regulator of cytokine signaling but its role in human cancer is not completely established. Here we report that, while SOCS1 is expressed in normal colonic epithelium and colon adenocarcinomas, its level decreases during progression of colon adenocarcinomas, the lowest level being found in the most aggressive stage and least differentiated carcinomas. Forced expression of SOCS1 in metastatic colorectal SW620 cells reverses many characteristics of Epithelial-Mesenchymal Transition (EMT), as highlighted by the disappearance of the transcription factor ZEB1 and the mesenchymal form of p120ctn and the re-expression of E-cadherin. Furthermore, miRNA profiling indicated that SOCS1 also up-regulates the expression of the mir-200 family of miRNAs, which can promote the mesenchymal-epithelial transition and reduce tumor cell migration. Accordingly, overexpression of SOCS1 induced cell morphology changes and dramatically reduced tumor cell invasion in vitro. When injected in nude mice, SOCS1-expressing SW620 cells induced metastases in a smaller number of animals than parental SW620 cells, and did not generate any adrenal gland or bone metastasis. Overall, our results suggest that SOCS1 controls metastatic progression of colorectal tumors by preventing the mesenchymal-epithelial transition (MET), including E-cadherin expression. This pathway may be associated with survival to colorectal cancer by reducing the capacity of generating metastases.
Copyright © 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Colorectal cancer; Invasion; Metastasis; SOCS1

Mesh:

Substances:

Year:  2014        PMID: 24726456      PMCID: PMC5528518          DOI: 10.1016/j.molonc.2014.03.014

Source DB:  PubMed          Journal:  Mol Oncol        ISSN: 1574-7891            Impact factor:   6.603


  52 in total

1.  The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop.

Authors:  H Yasukawa; H Misawa; H Sakamoto; M Masuhara; A Sasaki; T Wakioka; S Ohtsuka; T Imaizumi; T Matsuda; J N Ihle; A Yoshimura
Journal:  EMBO J       Date:  1999-03-01       Impact factor: 11.598

2.  Deletion of the carboxyl-terminal transactivation domain of MGF-Stat5 results in sustained DNA binding and a dominant negative phenotype.

Authors:  R Moriggl; V Gouilleux-Gruart; R Jähne; S Berchtold; C Gartmann; X Liu; L Hennighausen; A Sotiropoulos; B Groner; F Gouilleux
Journal:  Mol Cell Biol       Date:  1996-10       Impact factor: 4.272

3.  A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition.

Authors:  Cameron P Bracken; Philip A Gregory; Natasha Kolesnikoff; Andrew G Bert; Jun Wang; M Frances Shannon; Gregory J Goodall
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

4.  STAT6 and Ets-1 form a stable complex that modulates Socs-1 expression by interleukin-4 in keratinocytes.

Authors:  Julia Travagli; Martine Letourneur; Jacques Bertoglio; Josiane Pierre
Journal:  J Biol Chem       Date:  2004-06-15       Impact factor: 5.157

5.  Expression of SOCS-1, suppressor of cytokine signalling-1, in human melanoma.

Authors:  Zhuo Li; Dieter Metze; Dorothea Nashan; Carsten Müller-Tidow; Hubert L Serve; Christopher Poremba; Thomas A Luger; Markus Böhm
Journal:  J Invest Dermatol       Date:  2004-10       Impact factor: 8.551

6.  Sp2 regulates interferon-gamma-mediated socs1 gene expression.

Authors:  Martine Letourneur; Lyne Valentino; Julia Travagli-Gross; Jacques Bertoglio; Josiane Pierre
Journal:  Mol Immunol       Date:  2009-05-30       Impact factor: 4.407

7.  The transcriptional repressor ZEB1 promotes metastasis and loss of cell polarity in cancer.

Authors:  Simone Spaderna; Otto Schmalhofer; Mandy Wahlbuhl; Arno Dimmler; Katja Bauer; Aneesa Sultan; Falk Hlubek; Andreas Jung; Dennis Strand; Andreas Eger; Thomas Kirchner; Jürgen Behrens; Thomas Brabletz
Journal:  Cancer Res       Date:  2008-01-15       Impact factor: 12.701

Review 8.  Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic.

Authors:  Angeliki Voulgari; Alexander Pintzas
Journal:  Biochim Biophys Acta       Date:  2009-03-21

9.  IFNgamma-dependent, spontaneous development of colorectal carcinomas in SOCS1-deficient mice.

Authors:  Toshikatsu Hanada; Takashi Kobayashi; Takatoshi Chinen; Kazuko Saeki; Hiromi Takaki; Keiko Koga; Yasumasa Minoda; Takahito Sanada; Tomoko Yoshioka; Hiromitsu Mimata; Seiya Kato; Akihiko Yoshimura
Journal:  J Exp Med       Date:  2006-05-22       Impact factor: 14.307

10.  A core function for p120-catenin in cadherin turnover.

Authors:  Michael A Davis; Renee C Ireton; Albert B Reynolds
Journal:  J Cell Biol       Date:  2003-11-10       Impact factor: 10.539

View more
  13 in total

1.  A novel therapeutic approach for esophageal squamous cell carcinoma: suppressor of cytokine signaling-1 gene therapy.

Authors:  Chang-Han Chen; Shau-Hsuan Li
Journal:  J Thorac Dis       Date:  2017-06       Impact factor: 2.895

2.  Loss of FFAR2 promotes colon cancer by epigenetic dysregulation of inflammation suppressors.

Authors:  Pan Pan; Kiyoko Oshima; Yi-Wen Huang; Kimberle A Agle; William R Drobyski; Xiao Chen; Jianying Zhang; Martha M Yearsley; Jianhua Yu; Li-Shu Wang
Journal:  Int J Cancer       Date:  2018-03-30       Impact factor: 7.396

3.  Suppressor of cytokine signaling 1 modulates invasion and metastatic potential of colorectal cancer cells.

Authors:  Muriel David; Cécile Naudin; Martine Letourneur; Mélanie Polrot; Jack-Michel Renoir; Vladimir Lazar; Philippe Dessen; Serge Roche; Jacques Bertoglio; Josiane Pierre
Journal:  Mol Oncol       Date:  2014-03-25       Impact factor: 6.603

4.  Tumour-promoting role of SOCS1 in colorectal cancer cells.

Authors:  William S Tobelaim; Claudia Beaurivage; Audrey Champagne; Véronique Pomerleau; Aline Simoneau; Walid Chababi; Mehdi Yeganeh; Philippe Thibault; Roscoe Klinck; Julie C Carrier; Gerardo Ferbeyre; Subburaj Ilangumaran; Caroline Saucier
Journal:  Sci Rep       Date:  2015-09-22       Impact factor: 4.379

Review 5.  The role of small adaptor proteins in the control of oncogenic signalingr driven by tyrosine kinases in human cancer.

Authors:  Cécile Naudin; Clément Chevalier; Serge Roche
Journal:  Oncotarget       Date:  2016-03-08

Review 6.  Dysregulation of SOCS-Mediated Negative Feedback of Cytokine Signaling in Carcinogenesis and Its Significance in Cancer Treatment.

Authors:  Mengmeng Jiang; Wen-Wen Zhang; Pengpeng Liu; Wenwen Yu; Ting Liu; Jinpu Yu
Journal:  Front Immunol       Date:  2017-02-08       Impact factor: 7.561

Review 7.  The Emerging Role of Suppressors of Cytokine Signaling (SOCS) in the Development and Progression of Leukemia.

Authors:  Esra'a Keewan; Ksenia Matlawska-Wasowska
Journal:  Cancers (Basel)       Date:  2021-08-08       Impact factor: 6.639

8.  Clinical and molecular assessment of an onco-immune signature with prognostic significance in patients with colorectal cancer.

Authors:  Pankaj Ahluwalia; Ashis K Mondal; Meenakshi Ahluwalia; Nikhil S Sahajpal; Kimya Jones; Yasmeen Jilani; Gagandeep K Gahlay; Amanda Barrett; Vamsi Kota; Amyn M Rojiani; Ravindra Kolhe
Journal:  Cancer Med       Date:  2022-02-09       Impact factor: 4.452

9.  Characterization of sphere-forming HCT116 clones by whole RNA sequencing.

Authors:  Eunkyung Chung; Inkyung Oh; Kil Yeon Lee
Journal:  Ann Surg Treat Res       Date:  2016-03-30       Impact factor: 1.859

10.  Mechanism of suppressors of cytokine signaling 1 inhibition of epithelial-mesenchymal transition signaling through ROS regulation in colon cancer cells: suppression of Src leading to thioredoxin up-regulation.

Authors:  Sung-Hoon Jung; Su-Min Kim; Choong-Eun Lee
Journal:  Oncotarget       Date:  2016-09-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.